SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie Anderson, chairman and chief executive officer, will speak at the 2018 MedCity CONVERGE conference in a session entitled, “Early Diagnosis Through Predictive Biomarkers, Noninvasive Testing,” which will focus on opportunities to detect cancer at its earliest stages. The session will be held in Philadelphia on July 11 at 5:00 p.m. Eastern Time.
Ms. Anderson will join fellow executives in a discussion of emerging technologies and genomic discoveries – and what will be needed to translate these developments into actionable tests that ultimately transform how cancer is diagnosed and treated. She will share her perspectives on critical opportunities in lung cancer, where Veracyte has a commercialized genomic test that helps improve lung cancer diagnosis and is pursuing development of a simple nasal swab test to detect the disease at its earliest stages, when it is more treatable.
“The vast majority of our healthcare resources currently focus on treating cancer once it is diagnosed, which is often too late,” said Ms. Anderson. “However, advances in genomic science, sequencing technology and machine learning are providing tremendous new opportunities to detect cancer earlier, when it can be treated and potentially even prevented. This is particularly true in lung cancer, which still kills more Americans than the next three leading cancers combined.”
MedCity CONVERGE is a two-day conference that gathers executives representing technology disruptors, payers, providers, life science companies, venture capitalists and more to discuss how Artificial Intelligence, Big Data and Precision Medicine are changing the game in cancer. The 2018 event will take place in Philadelphia on July 11 and 12. More information can be found at https://events.medcitynews.com/converge/.
Veracyte, Inc. (Nasdaq: VCYT) is a leading genomic diagnostics company that is providing trustworthy and actionable answers that fundamentally improve patient care when current diagnostic tests are uncertain. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our belief that we have a strong foundation in place to drive revenue growth, our beliefs regarding momentum in our business and potential drivers of future growth, our expectations regarding full-year 2018 revenue and cash burn, our introduction of our Afirma Xpression Atlas platform, our expectations regarding our ability to receive Medicare reimbursement and expand commercialization of our Envisia Genomic Classifier, our expectations for the continued expansion in the commercialization of Percepta and our ability to drive revenue growth across our endocrinology and pulmonology franchises. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to our history of losses since inception; our ability to enhance the performance of our Afirma classifier; our ability to successfully transition to our next-generation Afirma Genomic Sequencing Classifier; the performance and acceptance of our Percepta and Envisia classifiers; our ability to increase usage of and reimbursement for the Afirma and Percepta classifiers and to obtain adequate reimbursement for our Envisia classifier, as well as any future products we may develop or sell; our ability to continue our momentum and growth; our dependence on a few payers for a significant portion of our revenue; and other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.